NeuroBo Pharmaceuticals (NRBO) News Today → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free NRBO Stock Alerts $3.06 -0.04 (-1.29%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineNeuroBo Pharmaceuticals, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.95) Per Share (NASDAQ:NRBO)americanbankingnews.com - April 26 at 1:36 AMNeuroBo Pharmaceuticals (NASDAQ:NRBO) Trading Up 2.6%americanbankingnews.com - April 25 at 1:50 AMNRBO: First Patient Dosed in Phase 1 Trial of DA-1726 for the Treatment of Obesity…finance.yahoo.com - April 23 at 1:48 PMHead to Head Review: NeuroBo Pharmaceuticals (NASDAQ:NRBO) vs. Ainos (NASDAQ:AIMD)americanbankingnews.com - April 19 at 2:22 AMNeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesityfinance.yahoo.com - April 17 at 12:48 PMNeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesityprnewswire.com - April 17 at 8:05 AMNeuroBo Pharmaceuticals Inc NRBOmorningstar.com - April 5 at 9:05 PMNeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHprnewswire.com - April 1 at 8:01 AMNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 28 at 2:05 PMNeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Updateprnewswire.com - March 28 at 8:01 AMNeuroBo Pharma Gets Approval To Proceed With Phase 2a Trial For DA-1241 To Treat MASH; Stock Up 8%markets.businessinsider.com - March 13 at 7:11 PMNeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHprnewswire.com - March 13 at 8:01 AMNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officerfinanznachrichten.de - March 4 at 11:30 AMNeuroBo Pharmaceuticals appoints Marshall Woodworth as CFOmsn.com - March 4 at 11:30 AMNeuroBo Pharmaceuticals Confirms Marshall Woodworth As New CFOmarkets.businessinsider.com - March 4 at 11:30 AMNeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officerfinance.yahoo.com - March 4 at 11:30 AMNeuroBo Receives First Site IRB Approval For DA-1726 Obesity Trial; Stock Gainsmarkets.businessinsider.com - February 29 at 10:20 AMNeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesityprnewswire.com - February 29 at 8:01 AMNeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conferencefinance.yahoo.com - February 12 at 9:54 AMNRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…finance.yahoo.com - February 6 at 4:09 PMNeuroBo’s DA-1726 Obesity Therapy Gets FDA IND Approvalmsn.com - February 2 at 8:33 AMWhy Obesity-Drug Maker NeuroBo Stock Is Trading Highermsn.com - February 1 at 1:03 PMNeuroBo Pharma'a IND Application For DA-1726 Gets FDA Clearancemarkets.businessinsider.com - February 1 at 1:03 PMNeuroBo Rises 48% On Receiving FDA Approval For IND Application For DA-1726markets.businessinsider.com - February 1 at 1:03 PMNeuroBo to begin Phase 1 testing of potential Wegovy rivalmsn.com - February 1 at 1:03 PMNeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesityfinance.yahoo.com - February 1 at 1:03 PMNeurobo Pharmaceuticals Inc (NRBO)investing.com - January 30 at 7:24 AMNeuroBo Announces Positive Pre-Clinical Safety Data Of DA-1241 In Combination With Sitagliptinmarkets.businessinsider.com - January 18 at 1:15 PMNRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…finance.yahoo.com - January 18 at 1:15 PMNeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHfinance.yahoo.com - January 18 at 8:14 AMNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirementfinanznachrichten.de - January 9 at 1:08 PMNeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirementfinance.yahoo.com - January 9 at 1:08 PMNeuroBo to Participate in Industry and Investor Conferences in Januaryfinance.yahoo.com - January 2 at 10:16 AMWhat's Going On With Clinical-Stage Biotech Firm NeuroBo Shares Today?msn.com - December 29 at 10:24 AMNeuroBo Pharmaceuticals Stock (NASDAQ:NRBO), Short Interest Reportbenzinga.com - December 28 at 1:18 PMNeuroBo Submits IND Application For Phase 1 Clinical Trial Of DA-1726; Stock Up In Pre-marketmarkets.businessinsider.com - December 28 at 1:18 PMNeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesityfinance.yahoo.com - December 28 at 1:18 PMNeuroBo Pharmaceuticals Stock (NASDAQ:NRBO) Dividends: History, Yield and Datesbenzinga.com - December 27 at 3:38 PMmarketbeat.com - December 21 at 6:05 AMNeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Splitfinance.yahoo.com - December 19 at 1:35 PMNeuroBo to Participate in Investor Conferences in Decemberfinance.yahoo.com - December 1 at 10:33 AMNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - November 14 at 7:07 PMNeuroBo Pharmaceuticals GAAP EPS of -$0.09 beats by $0.02msn.com - November 13 at 7:36 PMNeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 13 at 7:36 PMNeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.finance.yahoo.com - November 6 at 1:02 PMNeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conferencefinance.yahoo.com - October 17 at 9:06 AMNeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASHfinance.yahoo.com - September 15 at 8:20 AMNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - August 16 at 5:29 PMNeuroBo Appoints Hyung Heon Kim As CEOmarkets.businessinsider.com - August 14 at 5:32 PMNEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENTfinance.yahoo.com - August 14 at 8:07 AM Get NeuroBo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). NRBO Media Mentions By Week NRBO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRBO News Sentiment▼0.240.40▲Average Medical News Sentiment NRBO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRBO Articles This Week▼61▲NRBO Articles Average Week Get NeuroBo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Avalo Therapeutics News Aytu BioPharma News Pieris Pharmaceuticals News Talphera News Orgenesis News Minerva Neurosciences News Galecto News Cocrystal Pharma News VBI Vaccines News Kiora Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRBO) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
